A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-03-16) →
What happened
Inbiogen reported separate results for FY2025: revenue of US$4.36M (−10.6% year on year), an operating loss of US$3M and net income of US$4.03M (−63.9% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$4.36M |
|---|---|
| Revenue vs a year earlier | −10.6% |
| Operating profit | −US$3M |
| Net income | US$4.03M |
| Period | FY2025 (separate) |
| Filed | 2026-02-12, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260212800440 → open original filing |
Versions of this filing
- 2026-02-12Original (this page)
- 2026-03-16Amendment 1
Source: DART. Information only, not investment advice.